Differences in caffeine 3-demethylation activity among inbred mouse strains: A comparison of hepatic CYP1A2 gene expression between two inbred strains

Fundamental and Applied Toxicology

Volumn 40, Issue 2, 1997, Pages 228-237

  Casley, William L ^a,b,c   Menzies, J Allan ^a   Girard, Michel ^a   Larocque, Lyse ^a   Mousseau, Nicole ^a   Whitehouse, Larry W ^a   Moon, Thomas W ^b  

^a Bureau of Drug Research   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Sir FG Banting Research Centre   (Canada)

Author keywords

1,3,7 Trimethylxanthine; Caffeine; CYP1A2; Genetics; Inbred strains; Metabolism; Mice

Indexed keywords

CAFFEINE; CYTOCHROME P450;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; INBRED STRAIN; LIVER TOXICITY; MOUSE; NONHUMAN; XENOBIOTIC METABOLISM;

ANIMALIA;

EID: 26844573065     PISSN: 02720590     EISSN: None     Source Type: Journal    
DOI: 10.1006/faat.1997.2394     Document Type: Article

References (45)

1. Ahokas J. T., Pelkonen O., Ravenscroft P. J., Emmerson B. T. Effects of theophylline and caffeine on liver microsomal drug metabolizing mono-oxygenase in genetically AHH-responsive and non-responsive mice. Res. Comm. Substance Abuse. 2:1981;277-290.
2. Bedell M. A., Largaespada D. A., Jenkins N. A., Copeland N. G. Mouse models of human disease. Part II: Recent progress and future directions. Genes Devel. 11:1997;11-43.
3. Benson D., Boguski M., Lipman D. J., Ostell J. Genbank. Nucleic Acids Res. 22:1994;3441-3443.
4. Birge R. B., Bartalone J. B., Emeigh Hart S. G., Nishanian E. V., Tyson C. A., Khairallah E. A., Cohen S. D. Acetaminophen hepatotoxicity: Correspondence of selective protein arylation in human and mouse liverin vitro,in vivo. Toxicol. Appl. Pharmacol. 105:1990;472-482.
5. Bock K. W., Schrenk D., Forster A., Griese E. U., Morike K., Brockmeier D., Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 4:1994;209-218.
6. Burke M. D., Mayer R. T. Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and P-450 binding of phenoxazone and a homologous series of itsn. Chem. Biol. Interact. 45:1983;243-258.
7. Buters J. T. M., Tang B. K., Pineau T., Gelboin H. V., Kimura S., Gonzalez F. J. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2. Pharmacogenetics. 6:1996;291-296.
8. Butler M. A., Lang N. P., Young J. F., Caporaso N. E., Vineis P., Hayes R. B., Teitel C. H., Massengill J. P., Lawsen M. F., Kadlubar F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 2:1992;116-127.
9. Carrillo J. A., Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br. J. Clin. Pharmacol. 41:1996;605-608.
10. Casley W. L., Menzies J. A., Mousseau N., Girard M., Moon T. W., Whitehouse L. W. Increased basal expression of hepaticCyp1a1Cyp1a2. Pharmacogenetics. 7:1997;283-293.
11. Catteau A., Douriez E., Beaune P., Poisson N., Bonaitipellie C., Laurent P. Genetic polymorphism of induction of CYP1A1 (EROD) activity. Pharmacogenetics. 5:1995;110-119.
12. Chang C., Smith D. R., Prasad V. S., Sidman C. L., Nebert D. W., Puga A. Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics. 3:1993;312-321.
13. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
14. Denison M. S., Whitlock J. P. Xenobiotic-inducible transcription of cytochrome P450 genes. J. Biol. Chem. 270:1995;18175-18178.
15. Dietrich W. F., Miller J., Steen R., Merchant M. A., Damronboles D., Husain Z., Dredge R., Daly M. J., Ingalls K. A., Oconnor T. J., Evans C. A., Deangelis M. M., Levinson D. M., Kruglyak L., Goodman N., Copeland N. G., Jenkins N. A., Hawkins T. L., Stein L., Page D. C., Lander E. S. A comprehensive genetic map of the mouse genome. Nature. 380:1996;149-152.
16. Eaton D. L., Gallagher E. P., Bammler T. K., Kunze K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics. 5:1995;259-274.
17. Fernandez-Salguero P., Pineau T., Hilbert D. M., Mcphail T., Lee S. S. T., Kimura S., Nebert D. W., Rudikoff S., Ward J. M., Gonzalez F. J. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science. 268:1995;722-726.
18. Fujii-Kuriyama Y., Ema M., Mimura J., Matsushita N., Sogawa K. Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics. 5:1995;S149-S153.
19. Gielen J. E., Goujon F. M., Nebert D. W. Genetic regulation of aryl hydrocarbon hydroxylase induction. J. Biol. Chem. 247:1972;1125-1137.
20. Goasduff T., Dreano Y., Guillois B., Menez J. F., Berthou F. Induction of liver and kidney CYP1A1/1A2 by caffeine in rat. Biochem. Pharmacol. 52:1996;1915-1919.
21. Goldstein J. A., Linko P. Differential induction of 2,3,7,8-tetrachlorodibenzo-p. Mol. Pharmacol. 25:1984;185-191.
22. Harvison P. J., Guengerich F. P., Rashed M. S. Cytochrome P-450 isozyme selectivity in the oxidation of acetaminophen. Chem. Res. Toxicol. 1:1988;47-52.
23. Horn E. P., Tucker M. A., Lambert G., Silverman D., Zametkin D., Sinha R., Hartge T., Landi M. T., Caporaso N. E. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol. Biomarkers Prev. 4:1995;529-533.
24. Jayyosi Z., Knoble D., Muc M., Erick J., Thomas P. E., Kelley M. Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. J. Pharmacol. Exp. Ther. 273:1995;1156-1161.
25. Kimura S., Gonzalez F. J., Nebert D. W. The murine Ah locus. J. Biol. Chem. 259:1984a;10705-10713.
26. Kimura S., Gonzalez F. J., Nebert D. W. Mouse cytochrome P3-450: Complete cDNA and amino acid sequence. Nucleic Acids Res. 12:1984b;2917-2928.
27. 13. Mol. Cell. Biol. 6:1986;1471-1477.
28. Kinoshita T., Imamura J., Nagai H., Shimotohno K. Quantification of gene expression over a wide range by the polymerase chain reaction. Anal. Biochem. 206:1992;231-235.
29. 4. Nature (London). 277:1970;680-685.
30. Liu G., Gelboin H. V., Myers M. J. Role of cytochrome P450 1A2 in acetanilide 4-hydroxylation as determined with cDNA expression and monoclonal antibodies. Arch. Biochem. Biophys. 284:1991;400-406.
31. Nebert D. W. TheAh. Toxicology. 20:1989;153-174.
32. Nebert D. W., Mckinnon R. A., Puga A. Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer. DNA Cell. Biol. 15:1996;273-280.
33. Ono S., Hatanaka T., Hotta H., Tsutsui M., Satoh T., Gonzalez F. J. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics. 5:1995;143-150.
34. Okey A. B., Riddick D. S., Harper P. A. Molecular biology of the aromatic hydrocarbon (dioxin) receptor. Trends Pharmacol. Sci. 15:1994;226-232.
35. Patten C. J., Thomas P. E., Guy R. L., Lee M., Gonzalez F. J., Guengerich F. P., Yang C. S. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. 6:1993;511-518.
36. Peter R., Bocker R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydroxylation of chloroxazone as a specific probe for human liver cytochrome P450IIE1. Chem. Res. Toxicol. 3:1990;566-573.
37. Raffallimathieu F., Geneste O., Lang M. A. Characterization of two nuclear proteins that interact with cytochrome P-450 1A2 mRNA-Regulation of RNA binding and possible role in the expression of the Cyp1a2 gene. Eur. J. Biochem. 245:1997;17-24.
38. Relling M. V., Lin J. S., Ayers G. D., Evans W. E. Racial and gender differences inN. Clin. Pharmacol. Ther. 52:1992;643-658.
39. Rostami-Hodjegan A., Nurminen S., Jackson P. R., Tucker G. T. Caffeine urinary metabolite ratios as markers of enzyme activity: A theoretical assessment. Pharmacogenetics. 6:1996;121-149.
40. Ryu D. Y., Levi P. E., Fernandezsalguero P., Gonzalez F. J., Hodgson E. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. Mol. Pharmacol. 50:1996;443-446.
41. Sabath D. E., Broome H. E., Prytowsky M. B. Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T helper lymphocyte. Gene. 91:1990;185-191.
42. Schweikl H., Taylor J. A., Kitareewan S., Linko P., Nagorney D., Goldstein J. A. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics. 3:1993;239-249.
43. Swanson H. I., Bradfield C. A. The Ah-receptor: Genetics, structure and function. Pharmacogenetics. 3:1993;213-230.
44. Tassaneeyakul W., Birkett D. J., Veronese M. E., Mcmanus M. E., Tukey R. H., Quattrochi L. C., Gelboin H. V., Miners J. O. Specificity of substrate and inhibitor probes for human cytochromes-P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265:1993;401-407.
45. Whitehouse L. W., Paul C. J. Use of a discrete diode array spectrophotometer for the quantitative and qualitative analysis of cytochrome P-450. Mikrochim. Acta. 2:1987;65-72.